First AD

Second AD

 is an aggressive disease in which plasma cells grow uncontrollably. It is typically resistant to treatment and the prognosis for patients is poor. However, the genes that contribute to this behavior are not fully understood. Using single-cell transcriptomics, researchers led by 

, identified that CLPP, a protein in mitochondria, is overexpressed in high-risk cases and may also enable progression from earlier precursor cases to more advanced disease. Inhibiting CLPP genetically or through treatment with inobrodib reduced cancer cell growth, increased cell death and weakened the mitochondria of cancer cells in lab models. Additionally, combining CLPP inhibition with different therapies targeting cell metabolism or other mechanisms of protein breakdown worked more efficiently. These findings suggest that CLPP plays a key role in aggressive multiple myeloma, highlighting its potential as a therapeutic target. Learn more in 

"Our studies helped identify CLPP, and the CLP complex of which it is a part, as important mediators of aggressive myeloma behavior. This knowledge may help better predict patient outcomes in the near future and design even more effective treatments to eliminate myeloma cells," said Orlowski.

NO ADS

NOINDEX

NOFOLLOW

News

® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses. 

Canonical

The University of Texas MD Anderson Cancer Center

Cancer Centers

Partner

High-risk multiple myeloma is characterized by aggressive plasma cell proliferation and treatment resistance, with poor patient prognosis. The genetic contributors to this behavior remain unclear. Researchers have identified CLPP, a mitochondrial protein, as overexpressed in high-risk cases, potentially facilitating disease progression. Inhibiting CLPP, either genetically or with inobrodib, reduced cancer cell growth and increased apoptosis in lab models. Combining CLPP inhibition with therapies targeting cell metabolism or protein breakdown proved more effective. These findings underscore CLPP's role in aggressive myeloma, suggesting its potential as a therapeutic target.

Researchers at MD Anderson Cancer Center have identified a novel target for high-risk multiple myeloma.

Researchers Identify Novel Target for High-Risk Multiple Myeloma